Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Melanoma 3Sarcoma 2Ovarian Neoplasms 2Oligodendroglioma 2Neoplasm Metastasis 2Gliosarcoma 2Glioblastoma 2Fallopian Tube Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Astrocytoma 2Uveal Melanoma 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unspecified Childhood Solid Tumor, Protocol Specific 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Somatostatinoma 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Glioma 1Fibrolamellar hepatocellular carcinoma 1Endometrial Neoplasms 1

Interventions

sapanisertib 1aflibercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Fibrolamellar hepatocellular carcinoma × aflibercept × Clear all
NCT02159989 2025-10-20

Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

National Cancer Institute (NCI)

Phase 1 Completed
83 enrolled 21 charts
GastrointestinalGynecologic

Fibrolamellar hepatocellular carcinoma, Adenoma, Islet Cell, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡